Regional Infusion of a Class C TLR9 Agonist Enhances Liver Tumor Microenvironment Reprogramming and MDSC Reduction to Improve Responsiveness to Systemic Checkpoint Inhibition
… Abstract No. 158628: PERIO-01: Enabling Tumor Microenvironment Reprogramming by a TLR9 Agonist Using Pressure-Enabled Drug Delivery™ (PEDD™) to Address Intrahepatic Immunosuppression and Drug Delivery Barriers
… Antireflux Catheter Improves Tumor Targeting in Liver Radioembolization with Resin Microspheres
… Abstract No. 1793: Regional Administration of Class C CpG Oligodeoxynucleotides Results in Superior Intrahepatic TLR9 Activation and Immunomodulation Compared to Systemic Infusion
… HITM-SURE: Hepatic Immunotherapy for Metastases Phase Ib Anti-CEA CAR-T Study Utilizing Pressure Enabled Drug Delivery
… Abstract No. 9534: Phase 1b/2, Open Label, Multicenter, Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced Melanoma Who Are Naïve to Anti-PD-1/L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
… Abstract No. 9555: Phase 1b/2, Open Label, Multicenter Study of the Combination of SD-101 and Pembrolizumab in Patients with Advanced/Metastatic Melanoma Resistant to Anti-PD-1/PD-L1 Therapy (SYNERGY-001/KEYNOTE-184, NCT02521870)
… Abstract 6039: Phase 1b/2, Open Label, Multicenter Study of Intratumoral SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001/KEYNOTE-184, NCT02521870)
… STAT3 Inhibition Induces Bax-dependent Apoptosis in Liver Tumor Myeloid-Derived Suppressor Cells
… End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis
…